BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

...apraglutide could be a best-in-class therapy. The once-weekly injection would compete with GLP-2 analog Gattex teduglutide...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

...III trial could suffice for approval. If approved, apraglutide would compete with GLP-2 analog Gattex teduglutide...
...a second-generation product that could be best in class, with a once-weekly dosing advantage over Gattex...
BioCentury | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

...Takeda's Gattex gets pediatric approval FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK...
...CHEK1) - Checkpoint kinase 1; GLP-2 - Glucagon-like peptide-2 Chris Lieu, Staff Writer Fragmin, dalteparin Gattex, Revestive, teduglutide (ALX-0600) Imnovid...
BioCentury | May 1, 2018
Distillery Therapeutics

Autoimmune disease

...steps could include testing the peptide in additional models of IBD. Shire plc markets Gattex teduglutide...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...incidence of diverticulitis. Short bowel syndrome drug Gattex teduglutide was the next largest GI drug. Gattex...
BioCentury | Oct 2, 2017
Politics & Policy

FDA moving on complex generics

...competition.” The new guidance is aimed specifically at ANDAs for glucagon, liraglutide, nesiritide, teriparatide, and teduglutide...
BioCentury | Jul 25, 2016
Clinical News

Gattex regulatory update

...The European Commission approved an expanded label for Revestive teduglutide from Shire to treat short bowel...
...SBS. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Gattex ( Revestive - EU) teduglutide ( ALX-0600...
BioCentury | Jun 15, 2016
Company News

Shire licenses IBD biologic from Pfizer

...discussions with regulators. Shire already markets Orphan products for gastrointestinal diseases, including Revestive / Gattex teduglutide...
BioCentury | Jun 6, 2016
Clinical News

Revestive regulatory update

...EMA’s CHMP recommended expanding the label of Shire’s Revestive teduglutide to treat short bowel syndrome (SBS...
...August. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Revestive ( Gattex - U.S.) teduglutide ( ALX-0600...
BioCentury | Apr 25, 2016
Politics, Policy & Law

SCOTUS to the rescue?

...from Acorda [4] Ampyra dalfampridine from Acorda [2] Diprivan propofol from Fresenius Kabi [1] Gattex teduglutide...
Items per page:
1 - 10 of 183